KLB and hepatocellular carcinoma: An ongoing phase I/II study of FGF401 in patients with HCC or solid tumors with positive FGFR-4 and Klotho-β expression (NCT02325739) suggested promising clinical activity and a manageable safety profile that is consistent with FGFR-4 pathway inhibition.